JP2010529038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529038A5 JP2010529038A5 JP2010510505A JP2010510505A JP2010529038A5 JP 2010529038 A5 JP2010529038 A5 JP 2010529038A5 JP 2010510505 A JP2010510505 A JP 2010510505A JP 2010510505 A JP2010510505 A JP 2010510505A JP 2010529038 A5 JP2010529038 A5 JP 2010529038A5
- Authority
- JP
- Japan
- Prior art keywords
- patients
- imatinib
- leukemia
- treatment
- resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 9
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 6
- 229960002411 imatinib Drugs 0.000 description 6
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 5
- 230000035772 mutation Effects 0.000 description 4
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93265007P | 2007-06-01 | 2007-06-01 | |
| US60/932,650 | 2007-06-01 | ||
| PCT/US2008/065215 WO2008150957A2 (en) | 2007-06-01 | 2008-05-30 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014016309A Division JP2014111629A (ja) | 2007-06-01 | 2014-01-31 | 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
| JP2015229117A Division JP2016074700A (ja) | 2007-06-01 | 2015-11-24 | 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010529038A JP2010529038A (ja) | 2010-08-26 |
| JP2010529038A5 true JP2010529038A5 (cg-RX-API-DMAC7.html) | 2016-01-14 |
| JP5888853B2 JP5888853B2 (ja) | 2016-03-22 |
Family
ID=39639071
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510505A Active JP5888853B2 (ja) | 2007-06-01 | 2008-05-30 | 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
| JP2014016309A Pending JP2014111629A (ja) | 2007-06-01 | 2014-01-31 | 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
| JP2015229117A Pending JP2016074700A (ja) | 2007-06-01 | 2015-11-24 | 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014016309A Pending JP2014111629A (ja) | 2007-06-01 | 2014-01-31 | 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
| JP2015229117A Pending JP2016074700A (ja) | 2007-06-01 | 2015-11-24 | 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 |
Country Status (23)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2777704A3 (en) * | 2007-06-01 | 2015-01-21 | Wyeth LLC | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
| JP6026441B2 (ja) | 2011-03-04 | 2016-11-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | キナーゼ阻害剤としてのアミノキノリン |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| CN105143208B (zh) | 2013-02-21 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为激酶抑制剂的喹唑啉 |
| KR101733665B1 (ko) * | 2015-05-06 | 2017-05-10 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 진세노사이드 F1 또는 Rg3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물 |
| JP2022544700A (ja) * | 2019-08-22 | 2022-10-20 | バイオヘイブン・セラピューティクス・リミテッド | 筋萎縮性側索硬化症および関連障害の治療のためにtdp-43に結合する分子 |
| CN115944636A (zh) * | 2022-11-01 | 2023-04-11 | 华南师范大学 | 博舒替尼在抑制i-motif结构上的应用 |
| EP4746884A2 (en) * | 2023-07-21 | 2026-05-27 | Icahn School of Medicine at Mount Sinai | G9a/glp inhibitors and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| CA2434526C (en) * | 2001-01-25 | 2011-11-01 | Bristol Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
| EP2341133A1 (en) | 2001-10-05 | 2011-07-06 | Novartis AG | Mutated Abl kinase domains |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US20050010780A1 (en) * | 2003-07-09 | 2005-01-13 | Kane John Richard | Method and apparatus for providing access to personal information |
| CA2543163A1 (en) | 2003-11-06 | 2005-05-26 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
| TW200724548A (en) | 2005-04-25 | 2007-07-01 | Pfizer | Antibodies to myostatin |
| AU2006247322A1 (en) * | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
| AU2006270187A1 (en) | 2005-07-15 | 2007-01-25 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant SRC kinase polypeptides |
| KR101135220B1 (ko) | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
| WO2007056177A2 (en) * | 2005-11-04 | 2007-05-18 | Bristol-Myers Squibb Pharma Company | T315a and f317i mutations of bcr-abl kinase domain |
| EP2777704A3 (en) * | 2007-06-01 | 2015-01-21 | Wyeth LLC | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
-
2008
- 2008-05-30 EP EP14167958.9A patent/EP2777704A3/en not_active Withdrawn
- 2008-05-30 JP JP2010510505A patent/JP5888853B2/ja active Active
- 2008-05-30 BR BRPI0812355-1A2A patent/BRPI0812355A2/pt not_active Application Discontinuation
- 2008-05-30 PT PT151917564T patent/PT3002009T/pt unknown
- 2008-05-30 CA CA2688467A patent/CA2688467C/en active Active
- 2008-05-30 EP EP15191756.4A patent/EP3002009B1/en active Active
- 2008-05-30 US US12/129,935 patent/US11103497B2/en active Active
- 2008-05-30 CN CN2008800219346A patent/CN101686973B/zh active Active
- 2008-05-30 RU RU2009144128/15A patent/RU2464026C2/ru active
- 2008-05-30 CL CL200801577A patent/CL2008001577A1/es unknown
- 2008-05-30 SI SI200832178T patent/SI3002009T1/sl unknown
- 2008-05-30 DK DK12160638.8T patent/DK2478905T3/da active
- 2008-05-30 CA CA2868899A patent/CA2868899C/en active Active
- 2008-05-30 PA PA20088782301A patent/PA8782301A1/es unknown
- 2008-05-30 CA CA2964162A patent/CA2964162C/en active Active
- 2008-05-30 TW TW097120369A patent/TW200908982A/zh unknown
- 2008-05-30 PL PL15191756T patent/PL3002009T3/pl unknown
- 2008-05-30 WO PCT/US2008/065215 patent/WO2008150957A2/en not_active Ceased
- 2008-05-30 MX MX2009013069A patent/MX2009013069A/es active IP Right Grant
- 2008-05-30 PL PL12160638T patent/PL2478905T3/pl unknown
- 2008-05-30 ES ES15191756T patent/ES2881391T3/es active Active
- 2008-05-30 KR KR1020097027540A patent/KR101493543B1/ko active Active
- 2008-05-30 EP EP08769857A patent/EP2152267A2/en not_active Withdrawn
- 2008-05-30 SI SI200831212T patent/SI2478905T1/sl unknown
- 2008-05-30 ES ES12160638.8T patent/ES2477567T3/es active Active
- 2008-05-30 AU AU2008260070A patent/AU2008260070B9/en active Active
- 2008-05-30 DK DK15191756.4T patent/DK3002009T3/da active
- 2008-05-30 PT PT121606388T patent/PT2478905E/pt unknown
- 2008-05-30 EP EP12160638.8A patent/EP2478905B1/en active Active
- 2008-05-30 HU HUE15191756A patent/HUE055524T2/hu unknown
-
2009
- 2009-11-29 IL IL202407A patent/IL202407A0/en unknown
- 2009-11-30 ZA ZA200908480A patent/ZA200908480B/xx unknown
-
2014
- 2014-01-31 JP JP2014016309A patent/JP2014111629A/ja active Pending
- 2014-06-03 CY CY20141100395T patent/CY1115251T1/el unknown
-
2015
- 2015-11-24 JP JP2015229117A patent/JP2016074700A/ja active Pending
-
2021
- 2021-08-03 CY CY20211100693T patent/CY1124391T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jabbour et al. | Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options | |
| An et al. | BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review | |
| JP2009537552A5 (cg-RX-API-DMAC7.html) | ||
| JP2016521266A5 (cg-RX-API-DMAC7.html) | ||
| MX2009013781A (es) | Inhibidores de cinasa de proteina y metodos para el uso de los mismos. | |
| HRP20050318A2 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes | |
| JP2009513660A5 (cg-RX-API-DMAC7.html) | ||
| IL184673A0 (en) | COMPOUNDS POSSESSING B-Raf INHIBITORY ACTIVITY, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR PRODUCING AN ANTI-CANCER EFFECT IN WARM-BLOODED ANIMALS | |
| ATE494899T1 (de) | Zusammensetzung bestehend aus phy906 und chemotherapeutika | |
| TW200630105A (en) | Herbal composition PHY906 and its use in chemotherapy | |
| MX272108B (es) | Heterociclos sustituidos. | |
| DE602006010834D1 (de) | Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden | |
| JP2022554258A5 (cg-RX-API-DMAC7.html) | ||
| PL3002009T3 (pl) | Leczenie przewlekłej białaczki szpikowej opornej na imatynib z mutacją 1457T>C w genie bcrabl, wykorzystujące bosutynib | |
| WO2023245156A3 (en) | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | |
| WO2007120726A3 (en) | Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml | |
| IL195441A0 (en) | Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders | |
| JP2005530735A5 (cg-RX-API-DMAC7.html) | ||
| JP2018502089A5 (cg-RX-API-DMAC7.html) | ||
| CN109689657A (zh) | 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用 | |
| JP2010526884A5 (cg-RX-API-DMAC7.html) | ||
| Rej et al. | In this correspondence, preliminary data in 100 lithium users found that urine osmolality correlated with chronic kidney disease, diabetes mellitus, and hypothyroidism. We hypothesize that GSK-3β inhibition is a potential mechanism for lithium-associated medical illness | |
| RU2005134430A (ru) | Способ базисного лечения хронического вирусного гепатита c | |
| CN116075504A (zh) | 化合物的结晶形式 | |
| Üsküdar Teke et al. | Pleural effusion: a rare side effect of nilotinib—a case report |